Valo Health

Valo Health

Valo Health was founded in 2019 by David Berry, a former partner at Flagship Pioneering who previously co-founded the venture firm's AI therapeutics unit. Berry structured Valo as an independent entity, not a Flagship portfolio company, but retained ties to Flagship's network. The firm's wealth origin lies in Berry's prior work at Flagship, though it operates as a venture-backed standalone business. Valo's strategy centers on its Opus platform, which leverages human data (clinical, genomics, imaging) and AI to model disease biology and predict drug targets. The firm covers drug discovery, preclinical development, and early clinical trials — with named programs in oncology (e.g., a partnership with Bristol Myers Squibb announced in 2021 for up to $650M) and neurodegenerative disease (e.g., a tau-targeting program for Alzheimer's). Asset-class mix includes direct therapeutic development, collaborative partnerships with large pharma, and platform licensing. Geographic footprint is US-focused, with operations in Boston and New York; partnerships extend to Japan and Europe. Valo has raised over $500M from institutional investors including Flagship Pioneering, Google Ventures, and T. Rowe Price. The firm employs roughly 200 professionals as of late 2023. It maintains a separate philanthropic initiative, the Valo Health Foundation, focused on health equity. In May 2024, Valo announced a strategic collaboration with Novo Nordisk to develop treatments for cardiometabolic diseases, integrating its Opus platform with Novo's clinical data (per the firm, May 2024). Valo's structural differentiator is its 'data-first' drug discovery model — unlike most biotechs, it does not own a lab; all R&D occurs through computation and external CROs. This asset-light approach reduces fixed costs and enables permutable, iterative design. The firm's governance remains under Berry's control, with a board that includes senior partners from Flagship and Google Ventures.